Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis

Niklas Mueller, MD, Daniel Wicklein, PhD, Gregor Eisenwort, MD PhD, Juliana Schwaab, MD, Mohamad Jawhar, MD, Alexandra Boehm, MD, Harald Herrmann, MD, Gabriele Stefanzl, Gregor Hoermann, Wolfgang R. Sperr, MD, Michel Arock, PharmD,PhD, Andreas Reiter, MD, Udo Schumacher, MD, Peter Valent, MD

Blood (2016) 128 (22): 1955.

https://doi.org/10.1182/blood.V128.22.1955.1955

Published: 2016

Journal Articles

FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression

Ayako Nogami, MD PhD, Keigo Okada, MD, Gaku Oshikawa, MD PhD, Shinya Ishida, MD, Hiroki Akiyama, MD, Yoshihiro Umezawa, MD, Tetsuya Kurosu, MD PhD, Osamu Miura, MD PhD

Blood (2015) 126 (23): 1270.

https://doi.org/10.1182/blood.V126.23.1270.1270

Published: 2015

Journal Articles

Imipramine Blue Sensitively and Selectively Targets FLT3 and c-Kit Mutant Acute Myeloid Leukemia

Jonathan L. Metts, MD, Heath L. Bradley, M.S., Neil P. Shah, Reuben Kapur, PhD, Jack L. Arbiser, MD, PhD, Kevin D. Bunting, PhD

Blood (2015) 126 (23): 3688.

https://doi.org/10.1182/blood.V126.23.3688.3688

Published: 2015

Journal Articles

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

Mark J. Kiel, Thirunavukkarasu Velusamy, Delphine Rolland, Anagh A. Sahasrabuddhe, Fuzon Chung, Nathanael G. Bailey, Alexandra Schrader, Bo Li, Jun Z. Li, Ayse B. Ozel, Bryan L. Betz, Roberto N. Miranda, L. Jeffrey Medeiros, Lili Zhao, Marco Herling, Megan S. Lim, Kojo S. J. Elenitoba-Johnson

Blood (2014) 124 (9): 1460–1472.

https://doi.org/10.1182/blood-2014-03-559542

Published: 2014

Includes: Supplemental data

Journal Articles

Small Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells and Cause Cytotoxicity

Helena Mistry, Ph.D., Grace Hsieh, M.D., Sara Buhrlage, Ph.D, Min Huang, Ph.D., Eunmi Park, Ph.D., Gregory Cuny, Ph.D., Ilene Galinsky, ANP, Richard M. Stone, MD, Nathanael S Gray, PhD, Kalindi Parmar, PhD, Alan D. D'Andrea, MD

Blood (2013) 122 (21): 2906.

https://doi.org/10.1182/blood.V122.21.2906.2906

Published: 2013

Journal Articles

STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner

Lisa Schafranek, BSc., (Hons), Eva Nievergall, PhD, Jason A. Powell, BSc, PhD, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Deborah L. White, PhD, FFSc(RCPA), Timothy P. Hughes, MD, MBBS, FRACP, FRCPA, Tamara Leclercq, PhD

Blood (2013) 122 (21): 2705.

https://doi.org/10.1182/blood.V122.21.2705.2705

Published: 2013

Journal Articles

The Oncogenic Transcription Factor STAT5 Triggers Aberrant Expression Of CD25 (IL-2RA) In Neoplastic Stem Cells In Ph + CML

Irina Sadovnik, M.Sc., Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M, Wolfgang Warsch, Ph.D., Andrea Hoelbl, Ph.D., Katharina Blatt, MSc, Ph.D., Barbara Peter, D.V.M., Gabriele Stefanzl, Msc, Gregor Hoermann, M.D., Ph.D., Susanne Herndlhofer, Berthold Streubel, M.D., Wolfgang R Sperr, M.D., Christine Mannhalter, Ph.D., Veronika Sexl, MD, Peter Valent

Blood (2013) 122 (21): 3979.

https://doi.org/10.1182/blood.V122.21.3979.3979

Published: 2013

Journal Articles

Whole Genome Sequencing Of Chronic Myeloid Leukemia (CML)-Derived Induced Pluripotent Stem Cells (iPSC) Reveals Faithful Genocopying Of Highly Mutated Primary Leukemic Cells

Ivan Sloma, PharmD, PhD, Maria Teresa Mitjavila-Garcia, PhD, Olivier Feraud, Noufissa Oudrhiri, Lucie Tosca, PharmD, PhD, Sanaa El Marsafy, MD, PhD, Emilie Gobbo, Dominique Divers, Alexis Proust, Frank Griscelli, PharmD PhD, Gerard Tachdjian, MD, PhD, Marco A. Marra, PhD, Connie J Eaves, PhD, Annelise Bennaceur-Griscelli, MD, PhD, Ali G Turhan, MD, PhD

Blood (2013) 122 (21): 514.

https://doi.org/10.1182/blood.V122.21.514.514

Published: 2013

Journal Articles

A Single Chronic Myeloid Leukemia (CML) Stem Cell Harboring Both BCR-ABL and JAK2-V617F Mutation Modeled by Induced Pluripotency

Ivan Sloma, PharmD, PhD, Maria Teresa Mitjavila-Garcia, PhD, Olivier Feraud, Lucie Tosca, PharmD, PhD, Sanaa El Marsafy, MD, PhD, Emilie Gobbo, Dominique Divers, Alexis Proust, Marie Laure Bonnet, Frank Griscelli, PharmD PhD, Gerard Tachdjian, MD, PhD, Annelise Bennaceur-Griscelli, MD, PhD, Ali G Turhan, M.D., PhD

Blood (2012) 120 (21): 3728.

https://doi.org/10.1182/blood.V120.21.3728.3728

Published: 2012

Journal Articles

Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity

Lisa Schafranek, BSc., (Hons), Eva Nievergall, PhD, Jason A Powell, PhD, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Deborah L. White, PhD, FFSc(RCPA), Timothy P. Hughes, MD, MBBS

Blood (2012) 120 (21): 3736.

https://doi.org/10.1182/blood.V120.21.3736.3736

Published: 2012

Journal Articles

Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra

Irina Sadovnik, M.Sc., Peter Valent, MD, Els Lierman, PhD, Harald Herrmann, M.D., Barbara Peter, D.V.M., Verena Suppan, BSc, Gabriele Stefanzl, MSc, Winfried F Pickl, MD, Jan Cools, PhD, Peter Vandenberghe, MD, PhD

Blood (2012) 120 (21): 1760.

https://doi.org/10.1182/blood.V120.21.1760.1760

Published: 2012

Journal Articles

STAT5 as a CML target: STATinib therapies?

Ali G. Turhan

Blood (2011) 117 (12): 3252–3253.

https://doi.org/10.1182/blood-2011-01-332569

Published: 2011

Journal Articles

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

Erik A. Nelson, Sarah R. Walker, Ellen Weisberg, Michal Bar-Natan, Rosemary Barrett, Laurie B. Gashin, Shariya Terrell, Josephine L. Klitgaard, Loredana Santo, Martha R. Addorio, Benjamin L. Ebert, James D. Griffin, David A. Frank

Blood (2011) 117 (12): 3421–3429.

https://doi.org/10.1182/blood-2009-11-255232

Published: 2011

Includes: Supplemental data

Journal Articles

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.

Michal Bar-Natan, M.D, Erik A. Nelson, PhD, Sarah R. Walker, Ph.D., Rosemary Barrett, B.S., David A. Frank, MD, PhD

Blood (2009) 114 (22): 1905.

https://doi.org/10.1182/blood.V114.22.1905.1905

Published: 2009

Journal Articles

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

Erik A. Nelson, PhD, Sarah R. Walker, Ph.D., Alicia Kepich, B.S., Shariya Terrell, B.S., Laurie Gashin, B.S., David A. Frank, M.D., Ph.D.

Blood (2007) 110 (11): 2953.

https://doi.org/10.1182/blood.V110.11.2953.2953

Published: 2007

Journal Articles

DMT1-Independent Uptake of Non-Transferrin Bound Iron into Human Hepatoma Cells Is Selectively Modulated by T-Type Voltage-Dependent Calcium Channel Inhibitors.

Roozina Rafique, BSc, PhD, Monica S.D. Mascarenhas, BSc, MSc, Bala S. Ramesh, BSc, PhD, Kaila S. Srai, BSc, PhD, John B. Porter, MA,MD,FRCP,FRCPath

Blood (2006) 108 (11): 1542.

https://doi.org/10.1182/blood.V108.11.1542.1542

Published: 2006

NARROW

Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis

FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression

Imipramine Blue Sensitively and Selectively Targets FLT3 and c-Kit Mutant Acute Myeloid Leukemia

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

Small Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells and Cause Cytotoxicity

STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner

The Oncogenic Transcription Factor STAT5 Triggers Aberrant Expression Of CD25 (IL-2RA) In Neoplastic Stem Cells In Ph + CML

Whole Genome Sequencing Of Chronic Myeloid Leukemia (CML)-Derived Induced Pluripotent Stem Cells (iPSC) Reveals Faithful Genocopying Of Highly Mutated Primary Leukemic Cells

A Single Chronic Myeloid Leukemia (CML) Stem Cell Harboring Both BCR-ABL and JAK2-V617F Mutation Modeled by Induced Pluripotency

Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity

Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra

STAT5 as a CML target: STATinib therapies?

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells.

DMT1-Independent Uptake of Non-Transferrin Bound Iron into Human Hepatoma Cells Is Selectively Modulated by T-Type Voltage-Dependent Calcium Channel Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only